3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Phase 2
1
Phase 1/2
1
Status
Suspended
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Pancreatic Neoplasms
7
Breast Neoplasms
7
Colorectal Neoplasms
6
Stomach Neoplasms
5
Neoplasms
5
Sarcoma
3
Precision Cell Immunotherapy
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Mesothelioma, Malignant
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Hodgkin Disease
3
Glioblastoma
3
Esophageal Neoplasms
3
Wilms Tumor
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Mesothelioma
2
Melanoma
2
Lymphoma
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Ovarian Epithelial
2
Virus Diseases
1
Interventions
romidepsin
7
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Vincristine
4
Gemcitabine
4
Doxorubicin
4
Cyclophosphamide
4
Prednisone
3
Lenalidomide
3
Azacitidine
3
10-propargyl-10-deazaaminopterin
3
pembrolizumab
2
ixazomib
2
fludarabine phosphate
2
copanlisib
2
Whole-Body Irradiation
2
Vitamin B 12
2
Peripheral Blood Stem Cell Transplantation
2
Nivolumab
2
Mycophenolic Acid
2
Folic Acid
2
Etoposide
2
Dexamethasone
2
Cyclosporine
2
Bortezomib
2
venetoclax
1
tislelizumab
1
tazemetostat
1
relatlimab
1
prednisolone phosphate
1
pomalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Lymphoma, T-Cell, Peripheral
×
Drug Therapy
×
Clear all
NCT05138458
2023-11-13
IMAGINE
Myeloid Therapeutics
Phase 1/2
Suspended
40 enrolled